CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
- 18 March 2009
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 75 (6), 1337-1346
- https://doi.org/10.1124/mol.109.054833
Abstract
Genetic polymorphisms in VKORC1 and CYP2C9, genes controlling vitamin K1 (VK1) epoxide reduction and (S)-warfarin metabolism, respectively, are major contributors to interindividual variability in warfarin dose. The V433M polymorphism (rs2108622) in CYP4F2 has also been associated with warfarin dose and speculatively linked to altered VK1 metabolism. Therefore, the purpose of the present study was to determine the role of CYP4F2 and the V433M polymorphism in the metabolism of VK1 by human liver. In vitro metabolic experiments with accompanying liquid chromatography-tandem mass spectrometry analysis demonstrated that recombinant CYP4F2 (Supersomes) and human liver microsomes supplemented with NADPH converted VK1 to a single product. A screen of all commercially available P450 Supersomes showed that only CYP4F2 was capable of metabolizing VK1 to this product. Steady-state kinetic analysis with recombinant CYP4F2 and with human liver microsomes revealed a substrate Km of 8 to 10 μM. Moreover, anti-CYP4F2 IgG, as well as several CYP4F2-selective chemical inhibitors, substantially attenuated the microsomal reaction. Finally, human liver microsomes genotyped for rs2108622 demonstrated reduced vitamin K1 oxidation and lower CYP4F2 protein concentrations in carriers of the 433M minor allele. These data demonstrate that CYP4F2 is a vitamin K1 oxidase and that carriers of the CYP4F2 V433M allele have a reduced capacity to metabolize VK1, secondary to an rs2108622-dependent decrease in steady-state hepatic concentrations of the enzyme. Therefore, patients with the rs2108622 polymorphism are likely to have elevated hepatic levels of VK1, necessitating a higher warfarin dose to elicit the same anticoagulant response.Keywords
This publication has 41 references indexed in Scilit:
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humansNature Genetics, 2008
- Human Enteric Microsomal CYP4F EnzymesO-Demethylate the Antiparasitic Prodrug PafuramidineDrug Metabolism and Disposition, 2007
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime]Drug Metabolism and Disposition, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseThe New England Journal of Medicine, 2005
- Inhibition of human cytochromes P450 by components of Ginkgo bilobaJournal of Pharmacy and Pharmacology, 2004
- Tocopherols are metabolized in HepG2 cells by side chain ω-oxidation and consecutive β-oxidationFree Radical Biology & Medicine, 2001
- Cytochrome P4503A-Dependent Metabolism of Tocopherols and Inhibition by SesaminBiochemical and Biophysical Research Communications, 2000